Immunomodulating nanoparticulate composition
    3.
    发明授权
    Immunomodulating nanoparticulate composition 有权
    免疫调节纳米颗粒组成

    公开(公告)号:US09504760B2

    公开(公告)日:2016-11-29

    申请号:US13413377

    申请日:2012-03-06

    摘要: The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect.

    摘要翻译: 本发明涉及优选可喷雾的药物组合物,其包含优选地在150至300nm范围内的药学上可接受的基于蛋白质的纳米载体,以及预防或治疗量的用于预防和/或治疗过敏性和/ /或哺乳动物中下呼吸道的炎性疾病。 优选地,活性剂是CpG寡脱氧核苷酸(CpG-ODN),并且优选地,该组合物显示出延长的临床效果。

    Immunomodulating Nanoparticulate Composition
    4.
    发明申请
    Immunomodulating Nanoparticulate Composition 审中-公开
    免疫调节纳米颗粒组成

    公开(公告)号:US20120231041A1

    公开(公告)日:2012-09-13

    申请号:US13413377

    申请日:2012-03-06

    摘要: The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect.

    摘要翻译: 本发明涉及优选可喷雾的药物组合物,其包含优选地在150至300nm范围内的药学上可接受的基于蛋白质的纳米载体,以及预防或治疗量的用于预防和/或治疗过敏性和/ /或哺乳动物中下呼吸道的炎性疾病。 优选地,活性剂是CpG寡脱氧核苷酸(CpG-ODN),并且优选地,该组合物显示出延长的临床效果。